Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limitations of direct-to-consumer genetic testing for age-related macular degeneration.

European journal of ophthalmology - 1 Nov 2023

Shaheen Abdulla R, Uhr Joshua H, Sridhar Jayanth, Yannuzzi Nicolas A

Abstract excerpt

The availability of direct-to-consumer genetic testing (DTCGT) for age-related macular degeneration (AMD) provides the public with access to disease risk estimations that may be used to guide lifestyle adjustments. However, AMD development risk is more complex than can be captured by gene mutations alone. The methodologies employed by current DTCGTs to estimate AMD risk vary and are limited in several ways....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macular Degeneration

Source

Identifiers

PMID: 37211635
DOI: 10.1177/11206721231178054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limitations of direct-to-consumer genetic testing for age-related macular degeneration.PMID 37211635Read ↗

Direct-to-consumer personal genome testing for age-related macular degeneration.Semantic proximity Read ↗

Genetics and genetic testing for age-related macular degeneration.Semantic proximity Read ↗

Genetic testing for age-related macular degeneration: not indicated now.Semantic proximity Read ↗

Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?Semantic proximity Read ↗

Genetic Testing for Age-Related Macular DegenerationSemantic proximity Read ↗

Population differences in genetic risk for age-related macular degeneration and implications for genetic testing.Semantic proximity Read ↗

Genetic risk models in age-related macular degeneration.Semantic proximity Read ↗

Variations in predicted risks in personal genome testing for common complex diseases.Semantic proximity Read ↗

Genetic epidemiology: successes and challenges of genome-wide association studies using the example of age-related macular degeneration.Semantic proximity Read ↗

How Do Patients Respond to Genetic Testing for Age-related Macular Degeneration?Semantic proximity Read ↗

The regulation of direct-to-consumer genetic tests.Semantic proximity Read ↗

'Over-the-counter' genetic testing: what does it really mean for primary care?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.